Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Innate Pharma's Sezary Syndrome treatment shows strong results. Learn why IPHA stock offers potential with phase 2 data and ...
Pharmabiz5d
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Innate’s lacutamab gains FDA breakthrough therapy designation
Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...
Le Lézard6d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ...